Literature DB >> 2153246

Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP.

R Moorthy1, D A Thorley-Lawson.   

Abstract

We have analyzed the processing of the Epstein-Barr virus-encoded latent membrane protein (p63/LMP) in lymphoblastoid cell lines, Burkitt's lymphoma cell lines, and rodent fibroblasts transfected with the p63/LMP gene. Pulse-chase analysis by immunoprecipitation, under denaturing conditions, reveals a half-life of 2 h. This is due to turnover in the plasma membrane with cleavage of the protein, resulting in a 25,000-molecular-weight (p25) fragment derived from the carboxy-terminal portion of LMP. This fragment is rich in proline and acidic amino acids and sheds into the cytoplasm, where it appears to accumulate, being present in a six- to sevenfold molar excess over p63/LMP in immunoprecipitation analyses. p25 is, like p63/LMP, also phosphorylated (pp25) on serine and threonine residues, in the same ratio and to approximately the same extent as the intact p63/LMP molecule. Amino acid sequence analysis and carboxy-terminal labeling suggest that p25 is derived through a single cleavage adjacent to the sequence LGAPGGGPDNGPQDPD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153246      PMCID: PMC249178     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Authors:  M Rowe; H S Evans; L S Young; K Hennessy; E Kieff; A B Rickinson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein.

Authors:  K P Mann; D Thorley-Lawson
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

4.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

5.  Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus.

Authors:  V R Baichwal; B Sugden
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

6.  Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor.

Authors:  L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

7.  Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.

Authors:  J Gordon; L Walker; G Guy; G Brown; M Rowe; A Rickinson
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

8.  New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates.

Authors:  F T Liu; M Zinnecker; T Hamaoka; D H Katz
Journal:  Biochemistry       Date:  1979-02-20       Impact factor: 3.162

9.  Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells.

Authors:  B Kallin; J Dillner; I Ernberg; B Ehlin-Henriksson; A Rosén; W Henle; G Henle; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  Early events in Epstein-Barr virus infection provide a model for B cell activation.

Authors:  D A Thorley-Lawson; K P Mann
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  9 in total

1.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function.

Authors:  Tyson V Sharp; Hsei-Wei Wang; Andrew Koumi; Daniel Hollyman; Yoshio Endo; Hongtao Ye; Ming-Qing Du; Chris Boshoff
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3.

Authors:  M Sandberg; W Hammerschmidt; B Sugden
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1.

Authors:  R K Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

5.  Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus.

Authors:  T Mitchell; B Sugden
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.

Authors:  K M Izumi; E D Cahir McFarland; E A Riley; D Rizzo; Y Chen; E Kieff
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease.

Authors:  A Santón; A I Manzanal; E Campo; C Bellas
Journal:  Clin Mol Pathol       Date:  1995-08

8.  All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts.

Authors:  R K Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B site.

Authors:  L D Klaman; D A Thorley-Lawson
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.